Literature DB >> 24941199

Psychological interventions for individuals with cystic fibrosis and their families.

Lutz Goldbeck1, Astrid Fidika, Marion Herle, Alexandra L Quittner.   

Abstract

BACKGROUND: With increasing survival estimates for individuals with cystic fibrosis, long-term management has become an important focus. Psychological interventions are largely concerned with adherence to treatment, emotional and social adaptation and health-related quality of life. We are unaware of any relevant systematic reviews.
OBJECTIVES: To determine whether psychological interventions for people with cystic fibrosis provide significant psychosocial and physical benefits in addition to standard medical care. SEARCH
METHODS: Studies were identified from two Cochrane trials registers (Cystic Fibrosis and Genetic Disorders Group; Depression, Anxiety and Neurosis Group), Ovid MEDLINE and PsychINFO; unpublished trials were located through professional networks and Listserves. Most recent search of the Cystic Fibrosis and Genetic Disorders Group's register: 19 December 2013.Most recent search of the Depression, Anxiety and Neurosis Group's register: 12 November 2013. SELECTION CRITERIA: Randomised controlled studies of a broad range of psychological interventions evaluating subjective and objective health outcomes, such as quality of life or pulmonary function, in individuals of all ages with cystic fibrosis and their immediate family. We were interested in psychological interventions, including psychological methods within the scope of psychotherapeutic or psychosomatic mechanism of action (e.g. cognitive behavioural, cognitive, family systems or systemic, psycho-dynamic, or other, e.g. supportive, relaxation, or biofeedback), which were aimed at improving psychological and psychosocial outcomes (e.g. quality of life, levels of stress or distress, psychopathology, etc.), adaptation to disease management and physiological outcomes. DATA COLLECTION AND ANALYSIS: Three authors were involved in selecting the eligible studies and two of these authors assessed their risk of bias. MAIN
RESULTS: The review includes 16 studies (eight new studies included in this update) representing data from 556 participants. Studies are diverse in their design and their methods. They cover interventions with generic approaches, as well as interventions developed specifically to target disease-specific symptoms and problems in people with cystic fibrosis. These include cognitive behavioural interventions to improve adherence to nutrition or psychosocial adjustment, cognitive interventions to improve adherence or those associated with decision making in lung transplantation, a community-based support intervention and other interventions, such as self-hypnosis, respiratory muscle biofeedback, music therapy, dance and movement therapy, and a tele-medicine intervention to support patients awaiting transplantation.A substantial proportion of outcomes relate to adherence, changes in physical status or other specific treatment concerns during the chronic phase of the disease.There is some evidence that behavioural interventions targeting nutrition and growth in children (4 to 12 years) with cystic fibrosis are effective in the short term. Evidence was found that providing a structured decision-making tool for patients considering lung transplantation improves patients' knowledge of and expectations about the transplant, and reduces decisional conflict in the short term. One study about training in biofeedback-assisted breathing demonstrated some evidence that it improved some lung function measurements. Currently there is insufficient evidence for interventions aimed at other aspects of the disease process. AUTHORS'
CONCLUSIONS: Currently, insufficient evidence exists on psychological interventions or approaches to support people with cystic fibrosis and their caregivers, although some of the studies were promising. Due to the heterogeneity between studies, more of each type of intervention are needed to support preliminary evidence. Multicentre studies, with consequent funding implications, are needed to increase the sample size of these studies and enhance the statistical power and precision to detect important findings. In addition, multicentre studies could improve the generalisation of results by minimizing centre or therapist effects. Psychological interventions should be targeted to illness-specific symptoms or behaviours to demonstrate efficacy.

Entities:  

Mesh:

Year:  2014        PMID: 24941199     DOI: 10.1002/14651858.CD003148.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  23 in total

Review 1.  Singing as an adjunct therapy for children and adults with cystic fibrosis.

Authors:  J Yoon Irons; Peter Petocz; Dianna Theadora Kenny; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2019-07-12

Review 2.  Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes.

Authors:  Helen McGloin; Declan Devane; Caroline D McIntosh; Kirsty Winkley; Georgina Gethin
Journal:  Cochrane Database Syst Rev       Date:  2021-02-08

3.  Understanding adolescent and parent acceptability and feasibility experience in a large Type 1 diabetes mellitus behavioural trial.

Authors:  D H Grossoehme; E Smith; D Standiford; N Morwessel; J Kichler; D M Maahs; K Driscoll; M Seid
Journal:  Diabet Med       Date:  2019-02-12       Impact factor: 4.359

4.  Quality of life among German parents of children with cystic fibrosis: the effects of being a single caregiver.

Authors:  Astrid Wallenwein; Mona Schwarz; Lutz Goldbeck
Journal:  Qual Life Res       Date:  2017-08-01       Impact factor: 4.147

Review 5.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

6.  Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention.

Authors:  Maureen E Lyon; Jessica D Thompkins; Karen Fratantoni; Jamie L Fraser; Sandra E Schellinger; Linda Briggs; Sarah Friebert; Samar Aoun; Yao Iris Cheng; Jichuan Wang
Journal:  BMJ Support Palliat Care       Date:  2019-07-25       Impact factor: 4.633

7.  Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis.

Authors:  Astrid Fidika; Marion Herle; Lutz Goldbeck
Journal:  BMC Pulm Med       Date:  2014-12-16       Impact factor: 3.317

8.  A web-based psychological support program for caregivers of children with cystic fibrosis: a pilot study.

Authors:  Astrid Fidika; Marion Herle; Christine Lehmann; Christa Weiss; Christine Knaevelsrud; Lutz Goldbeck
Journal:  Health Qual Life Outcomes       Date:  2015-02-04       Impact factor: 3.186

9.  Resilience in adolescents and young adults with cystic fibrosis: A pilot feasibility study of the promoting resilience in stress management intervention.

Authors:  Demet Toprak; Laura Nay; Sharon McNamara; Abby R Rosenberg; Margaret Rosenfeld; Joyce P Yi-Frazier
Journal:  Pediatr Pulmonol       Date:  2019-12-03

Review 10.  Impact of telemedicine on health outcomes in children with medical complexity: an integrative review.

Authors:  Federico Ferro; Alberto Eugenio Tozzi; Ilaria Erba; Immacolata Dall'Oglio; Andrea Campana; Corrado Cecchetti; Caterina Geremia; Maria Luisa Rega; Gloria Tontini; Emanuela Tiozzo; Orsola Gawronski
Journal:  Eur J Pediatr       Date:  2021-07-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.